

**Genomic Medicine x AI Startup Xcoo, Inc.
has formed with H.U. Group Holdings, Inc.
a business and capital alliance founded on the mutual
commitment toward providing analytical services
in the field of next-generation genomics and omics medicine.**

Tokyo, Japan, October 23, 2023 --- We are pleased to announce that Xcoo, Inc. have reached a memorandum of understanding with SRL, Inc., a subsidiary of H.U. Group Holdings, Inc., with the aim of creating analysis services in the field of next-generation genomics and omics medicine[※]. Additionally, we have conducted a third-party allotment of new shares to MSF Capital Partners G.K. taking on the role of H.U. Group's corporate venture capital function.

The Background and Purpose of the Capital Business Alliance

For over the last decade, we have been an active contributor in the vastly developing field of genomic medicine. Through our endeavors we remain committed to be the catalyst for the social adaptation of genomic information based precision medicine.

Since 2019, when insurance coverage for cancer gene panel testing (comprehensive cancer genome profiling) was put in effect, the clinical application of genomic medicine appears feasible in the upcoming years. However, even with this pivotal medical implementation, there will still remain a large population unable to appreciate its benefits. This group includes patients with variations of cancer that cannot be elucidated by traditional panel testing, as well as those diagnosed with rare and intractable diseases that remain untreatable. To combat these challenges, whole-genome sequencing (WGS) is viewed as the paradigm shifting innovation for personalized medicine, which has invoked government led initiatives such as the Action Plan for Whole Genome Analysis of Japan.

We possess industry leading information technologies capable of analyzing and visualizing genome sequence data generated by next-generation sequencers. With these advanced tools paired with our reporting technology to automatically collect, organize, and report information related to genetic variants and diseases, we provide assistance to healthcare professionals in clinical settings. H.U. Group and SRL possess unique qualities such as their nationwide sample collection network, testing techniques from sample receipt to analysis using next-generation sequencers, and highly automated operational capabilities. Through collaboration between Xcoo and SRL, we aim to promote the creation and clinical implementation of next-generation genomics and omics medical diagnostic systems that assist in medical decisions such as drug efficacy prediction, prognosis prediction, monitoring, and prevention. Additionally, Xcoo has strengthened its financial foundation through investment from MSF.

Through this partnership, Xcoo, SRL, and H.U. Group plan to jointly provide a one-stop whole-genome analysis service from sample receipt to reporting in an effort to assist patients with diseases and the healthcare professionals who care for them. We are dedicated in our contribution to the development of next-generation genomic and omics medicine as well as our growth as a business enterprise.



※Genomic and Omics Medicine: Genomic medicine is a rapidly advancing field that utilizes an individual's genetic information to be able to prevent, diagnose, treat, and prognose various diseases, including cancer and rare diseases. Omics medicine encompasses comprehensive analysis of various biomolecules such as DNA, RNA, proteins, and metabolites, and leverages this information for medical purposes. Genomic and omics medicine, which extends genomic medicine to omics medicine, is expected to promote the realization of personalized precision medicine, offering the potential for the next generation of finely-tuned healthcare.

About Xcoo

A start-up company originating from the University of Tokyo, specialized in genome analysis and bioinformatics. Xcoo has been developing and operating Chrovis, a total solution software for genomic and bioinformatics analyses. The company has received numerous startup-related awards, including the MEXT Minister's Award at Adcademic Startups 2019. Chrovis Clinical Annotation Cancer Genome Reporting (tentative name) has been designated for priority review by the Ministry of Health, Labor and Welfare concerning Software as a Medical Device (SaMD).

Headquarters : Headquarters : 2-40-8, Hongo, Bunkyo-ku, Tokyo 113-0033 JAPAN

CEO : Kunihiro Nishimura, Ph.D.

Established : April, 2011

Web site : <https://xcoo.co.jp/>

- Xcoo's Business :
- Development and operation of Chrovis, a total solution for genome and bioinformatics analysis
 - Development of systems for high-speed data processing by parallel and distributed computing
 - Development of systems for data analysis/visualization based on state-of-the-art algorithms

Recruitment information

We, Xcoo, are recruiting engineers and other professionals who are willing to assist in bridging information technology toward social implementation along with us. To accomplish this, we have our business concept is founded in, "organizing and analyzing large volumes of complex information (*data intelligence*), presenting them in a format that is comprehensible to any person (*visualization*), and ultimately leading to actions (*decision-making*). We welcome those who could share our mission and are willing to take on challenges together with our highly-skilled engineers and other professional staff.

Web site : <https://xcoo.co.jp/recruit.html>

Contact us

PR Team : pr@xcoo.jp